vepoloxamer

On Monday, Mast Therapeutics Inc (NYSE: MSTX) provided an update on its business strategy and the clinical development of its product candidate AIR001. Laidlaw’s Yale Jen maintains a Neutral rating on the company. Update “Management reiterated that MSTX will focus on clinical...

Shares of Mast Therapeutics Inc (NYSE: MSTX) fell 83 percent in Tuesday’s after-hours session after the company announced its phase-3 EPIC trial of vepoloxamer for the treatment of sickle cell disease patients experiencing vaso-occlusive crisis failed to meet its primary efficacy...